GSK plc 6-K, filed Oct 13, 2022
GSK plc (GSK)
6-K
2022-10-13
For: 2022-10-13
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on October 13, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 13 October 2022, London UK
GSK's older adult respiratory syncytial virus (RSV) vaccine
candidate shows 94.1% reduction in severe RSV disease and overall
vaccine efficacy of 82.6% in pivotal trial
●
Data
to be presented at IDWeek 2022 showed overall vaccine efficacy
against RSV-lower respiratory tract disease (LRTD) in adults aged
60 years and above, with a favourable safety profile
●
Consistent
high vaccine efficacy observed against LRTD in severe disease
(94.1%), adults aged 70-79 years (93.8%) and in adults with
underlying comorbidities (94.6%)
●
High
vaccine efficacy is consistent across RSV A and B
strains
GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III
trial results for its respiratory syncytial virus (RSV) vaccine
candidate for adults aged 60 years and above to be presented at
IDWeek 2022. The vaccine candidate was highly efficacious,
demonstrating overall vaccine efficacy of 82.6% (96.95% CI,
57.9-94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower
respiratory tract disease (RSV-LRTD), meeting the trial's primary
endpoint.
Consistent high vaccine efficacy was also observed across a range
of pre-specified secondary endpoints, highlighting the impact the
vaccine candidate could have on the populations most at risk of the
severe outcomes of RSV. Efficacy against severe RSV-LRTD, defined
as LRTD with at least two lower respiratory signs or assessed as
severe by the investigator and confirmed by the external
adjudication committee, was 94.1% (95% CI, 62.4-99.9, 1 of 12,466
vs. 17 of 12,494). In participants with pre-existing comorbidities,
such as underlying cardiorespiratory and
endocrinometabolic conditions,
vaccine efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 vs. 18 of
4,861), with 93.8% (95% CI, 60.2-99.9, 1 of 4,487 vs. 16 of 4,487)
efficacy observed in adults aged 70-79 years.
Vaccine efficacy against LRTD was consistent across both RSV-A and
RSV-B subtypes (84.6%; CI 32.1-98.3, 2 of 12,466 vs. 13 of 12,494
and 80.9%; CI 49.4-94.3, 5 of 12,466 vs. 26 of 12,494
respectively), consistent with the robust neutralising antibody
response generated against both subtypes. See Figure 1: Vaccine
efficacy against first episodes of RSV-confirmed LRTD and
RSV-confirmed ARI (modified exposed set).
Tony Wood, GSK Chief Scientific Officer, said:
"These are truly exceptional results given that today RSV remains
one of the major infectious diseases without a vaccine, despite
over 60 years of research. We believe that with the high vaccine
efficacy demonstrated in this pivotal trial, our vaccine candidate
has the potential to help reduce the significant global burden of
RSV-associated disease in older adults, including those at the
greatest risk of severe outcomes due to their age or underlying
comorbidities."
The vaccine was well tolerated with a favourable safety profile.
The observed solicited adverse events were typically
mild-to-moderate and transient, the most frequent being injection
site pain, fatigue, myalgia, and headache.
Regulatory submissions based on the phase III data are anticipated
in the second half of 2022. GSK's RSV vaccine candidate for older
adults contains a recombinant subunit prefusion RSV F glycoprotein
antigen (RSVPreF3) combined with GSK's proprietary
AS01E adjuvant. There
are currently no RSV vaccines approved anywhere in the
world.
See Figure 1: Vaccine efficacy against first episodes of
RSV-confirmed LRTD and RSV-confirmed ARI (modified exposed
set)
http://www.rns-pdf.londonstockexchange.com/rns/7703C_1-2022-10-13.pdf
About the AReSVi-006 trial
The
AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial is a randomised,
placebo-controlled, observer-blind, multi-country trial to
demonstrate the efficacy of a single dose of GSK's adjuvanted
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above. Approximately 25,000 participants were enrolled from 17
countries.
This phase III efficacy trial is part of a comprehensive RSV
evidence-generation programme conducted by GSK. It will continue to
evaluate an annual revaccination schedule and longer-term
protection over multiple seasons following one dose of the RSV
vaccine candidate.
AReSVi-006
is closely monitored for safety, with safety data reviewed
internally and by an external Independent Data Monitoring Committee
on an ongoing basis.
The GSK
proprietary AS01 adjuvant system contains QS-21 Stimulon®
adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of
Agenus Inc.
About respiratory syncytial virus (RSV) in adults
RSV is a common contagious virus affecting the lungs and breathing
passages. It is one of the major remaining infectious diseases for
which there is currently no vaccine or specific treatment available
for adults. Older adults are at high risk for severe disease due to
age-related decline in immunity and underlying conditions. RSV can
exacerbate conditions, including chronic obstructive pulmonary
disease (COPD), asthma and chronic heart failure and can lead to
severe outcomes, such as pneumonia, hospitalisation, and death. RSV
causes over 420,000 hospitalisations each year and 29,000 deaths in
adults in industrialised countries. Adults with underlying
conditions are more likely to seek medical advice and have higher
hospitalisation rates than adults without these
conditions.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
October 13, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|